Copyright: ©Author(s) 2026.
World J Cardiol. Apr 26, 2026; 18(4): 118879
Published online Apr 26, 2026. doi: 10.4330/wjc.v18.i4.118879
Published online Apr 26, 2026. doi: 10.4330/wjc.v18.i4.118879
Table 1 Baseline characteristics of included studies, mean ± SD
| Ref. | Year | Study type | Patient population | Age | Sex (female) | |||
| Finerenone | Control | Finerenone | Control | Finerenone | Control | |||
| Solomon et al[18] | 2024 | RCT | 3003 | 2998 | 71.9 ± 9.6 | 72.0 ± 9.7 | 1355 | 1377 |
| Filippatos et al[19] | 2016 | RCT | 834 | 221 | 70.83 ± 10.17 | 72.4 ± 9.9 | 188 | 51 |
| Sato et al[20] | 2016 | RCT | 59 | 13 | 76.11 ± 9.06 | 76.5 ± 10.89 | 18 | 1 |
| Pitt et al[21] | 2013 | RCT | 264 | 65 | 71.27 ± 8.24 | 71.74 ± 7.54 | 52 | 15 |
- Citation: Mylavarapu M, Kiyani M, Ndakotsu A, Vats V, Karnan N, Palaparthi EC, Anjum M, Kodali LSM, Jamshed A, Cabrera FEP. Clinical outcomes of finerenone in heart failure: A systematic review and meta-analysis. World J Cardiol 2026; 18(4): 118879
- URL: https://www.wjgnet.com/1949-8462/full/v18/i4/118879.htm
- DOI: https://dx.doi.org/10.4330/wjc.v18.i4.118879
